Drugs / ORBCEL-C
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03042143 | Jan 2019 → Apr 2026 overdue | acute respiratory distress syndrome | Belfast Health and Social Care Trust | Active not recruiting | Missed primary |
| Phase 1/2 | NCT02997878 | Dec 2018 → Nov 2023 overdue | autoimmune hepatitis, sclerosing cholangitis | University of Birmingham | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORBCEL-C | “Determine dose safety of ORBCEL-C™ (selected Mesenchymal stromal cells derived from human umbilical cord)” NCT02997878 ↗2“ORBCEL-C is a population of CD362 enriched umbilical cord-derived MSCs.” PMID 34746723 ↗ Oct 2021 |
| Modality | Cell therapy | “Selected Mesenchymal Stromal Cells derived from human umbilical cord” NCT02997878 ↗ |
| Route | Intravenous | “single intravenous infusion of ORBCEL-C™” NCT02997878 ↗ |